Eric Padron, MD is an Associate Member and Scientific Director in the Malignant Hematology Department at the H. Lee Moffitt Cancer Center with a research focus in chronic myelomonocytic leukemia (CMML), clonal hematopoesis (CH), and chronic myeloid neoplasms. His translational laboratory seeks to identify and implement novel discoveries towards the managment of patients with CMML and CH. Mechanistic studies to understand the molecular underpinnings of chronic myelomonocytic leukemia constitute a large portion of his laboratory’s efforts. The central focus of these studies are to understand both the cell intrinsic (clonal evolution) and cell extrinsic (acute inflammation) targetable factors that are responsible for disease initiation and progression.  This urgency is born out of Dr. Padron’s CMML clinic in which most of his patients succumb to their disease. To that end, Dr Padron has developed a CMML PDX model that can recapitulate the human condition so that novel therapeutics can be preclinically tested. The Padron lab has generated over 2000 CMML PDX from over 100 unique patients and tested approximately 20 compounds.  Because of these efforts, Dr. Padron has successfully translated his lab discoveries into several clinical trials in the CMML. This is exemplified by his bench-to-bedside efforts that have led to the successful completion of a phase 1 and 2 trial testing ruxolitinib in CMML. He has been awarded several grants for his genomic studies in the MDS and CMML fields, including the American Society of Hematology Scholar Award, the Evans MDS Foundation Fellow Award, the NCI to study the therapeutic candidacy of long noncoding RNAs and to dissect inflammation in CMML, and a large MDS Foundation grant to study molecular aspects of CMML in 1000 patients. Dr. Padron has published over 215 peer-reviewed manuscripts in the area of myeloid malignancies.